




RealRate

PHARMACEUTICAL 2022

Xeris Biopharma Holdings Inc
Rank 370 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Xeris Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Xeris Biopharma Holdings Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 102% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	142,596
Cost of Goods Sold	0
Intangible Assets	154,309
Liabilities, Current	79,040
Liabilities, Non-Current	1,676
Other Assets	829
Other Compr. Net Income	-37
Other Expenses	13,868
Other Liabilities	128,414
Other Net Income	-7,569
Other Revenues	49,590
Property and Equipment	6,627
Research and Development	25,160
Selling, General and Administrative Expense	125,718

Output Variable	Value in 1000 USD
Assets	304,361
Liabilities	209,130
Expenses	164,746
Revenues	49,590
Stockholders Equity	95,231
Net Income	-122,725
Comprehensive Net Income	-122,744
BaseVar	367,716
ECR before Limited Liability	33%
Economic Capital Ratio	173%